StockWatch
·
Specialty Chemicals
Board Meeting6 Nov 2026, 02:47 pm

Black Rose Industries: consolidated PAT +137% YoY on margin rebound, revenue up 4%

AI Summary

Black Rose Industries' consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹10.49 Cr, up 137% year-on-year from ₹4.43 Cr in Q2 FY26, while revenue from operations grew a much more modest 4.4% YoY to ₹87.68 Cr (₹83.98 Cr a year ago). Sequentially the print was flat — PAT up just 0.9% QoQ and revenue down 1.6% QoQ from Q1 FY27's ₹10.39 Cr PAT and ₹89.08 Cr revenue — so the YoY jump, not the QoQ number, is the real story this quarter; with revenue barely moving QoQ, the sequential comparison itself carries little signal beyond confirming the business has held its new, higher margin level. The entire YoY profit surge is a margin story rather than a volume story. Total expenses fell to 87.8% of revenue from 93.2% a year ago, lifting operating margin (OPM) to 13.8% from 8.6% YoY and net margin (NPM) to 11.5% from 5.3% YoY. Sequentially, margins eased slightly — OPM from 16.1% to 13.8% and NPM roughly flat at 11.5% vs 11.53% — as the expense ratio ticked up from 85.3% to 87.8% of revenue QoQ. EPS tracked the profit line: ₹2.06 this quarter versus ₹0.87 a year ago and ₹2.04 last quarter. No brokerage estimates for Black Rose could be found in a web search (public trackers show zero analysts covering the stock), so there is no street print to grade against; vsStreet is unknown. Against the company's own May 2026 concall guidance — subdued near-term distribution demand offset by higher pricing and a strong merchant-export pipeline, plus a positive manufacturing/acrylamide export outlook — this quarter's combination of muted topline growth with sharp margin recovery is broadly on-script, so the result reads as a guidance-met quarter rather than a beat or miss. No separate management press release accompanied this filing to cross-check against. At the same board meeting (6 November 2026) the company also approved Srishti Gour's appointment as Company Secretary and Compliance Officer; the VP Innovation's resignation in October and the routine SEBI KYC/insider-trading-window items from September are unrelated to the financial print. The consolidated accounts continue to carry B.R. Chemicals Co. (Japan) as discontinued operations pending its wind-up, a step the board further approved in July 2026 — its drag is now immaterial (a ₹0.0021 Cr loss this quarter) and should fully exit the consolidated book once the wind-up completes. Going into Q3, the key swing factors remain whether the acrylamide export pickup and merchant-export order pipeline flagged in management's prior commentary convert the current margin gain into faster revenue growth, and whether the long-flagged Specialty Amines project decision materialises.

Key Highlights

  • Consolidated PAT ₹10.49 Cr, up 137% YoY from ₹4.43 Cr (Q2 FY26); up just 0.9% QoQ from ₹10.39 Cr (Q1 FY27)
  • Revenue from operations ₹87.68 Cr, +4.4% YoY from ₹83.98 Cr; -1.6% QoQ from ₹89.08 Cr
  • Operating margin expanded to 13.8% from 8.6% YoY (eased from 16.1% QoQ); net margin 11.5% vs 5.3% YoY (flat QoQ)
  • EPS ₹2.06 vs ₹0.87 a year ago and ₹2.04 last quarter
  • No exceptional items in either period; standalone and consolidated PAT differ by only ₹0.002 Cr
  • Japan subsidiary B.R. Chemicals Co. remains classified as discontinued operations pending wind-up (board-approved July 2026); quarter's discontinued loss just ₹0.0021 Cr
  • Board separately appointed Srishti Gour as Company Secretary & Compliance Officer at the same meeting